Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial by Liu, X, Munro, APS, Wright, A, Feng, S, Janani, L, Aley, PK, Babbage, G, Baker, J, Baxter, D, Bawa, T, Bula, M, Cathie, K, Chatterjee, K, Dodd, K, Enever, Y, Fox, L, Qureshi, E, Goodman, AL, Green, CA, Haughney, J, Hicks, A, Jones, CE, Kanji, N, van der Klaauw, AA, Libri, V, Llewelyn, MJ, Mansfield, R, Maallah, M, McGregor, AC, Minassian, AM, Moore, P, Mughal, M, Mujadidi, YF, Belhadef, HT, Holliday, K, Osanlou, O, Osanlou, R, Owens, DR, Pacurar, M, Palfreeman, A, Pan, D, Rampling, T, Regan, K, Saich, S, Saralaya, D, Sharma, S, Sheridan, R, Stokes, M, Thomson, EC, Todd, S, Lambe, T, Snape, MD

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the C... by Liu, X, Munro, APS, Feng, S, Janani, L, Aley, PK, Babbage, G, Baxter, D, Bula, M, Cathie, K, Chatterjee, K, Dejnirattisai, W, Dodd, K, Enever, Y, Qureshi, E, Goodman, AL, Green, CA, Harndahl, L, Haughney, J, Hicks, A, van der Klaauw, AA, Kwok, J, Libri, V, Llewelyn, MJ, McGregor, AC, Minassian, AM, Moore, P, Mughal, M, Mujadidi, YF, Holliday, K, Osanlou, O, Osanlou, R, Owens, DR, Pacurar, M, Palfreeman, A, Pan, D, Rampling, T, Regan, K, Saich, S, Serafimova, T, Saralaya, D, Screaton, GR, Sharma, S, Sheridan, R, Sturdy, A, Supasa, P, Thomson, EC, Todd, S, Twelves, C, Read, RC, Charlton, S, Hallis, B, Ramsay, M, Andrews, N, Lambe, T, Nguyen-Van-Tam, JS, Cornelius, V, Snape, MD, Faust, SN